Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001829126-23-003606
Filing Date
2023-05-19
Accepted
2023-05-19 09:22:31
Documents
16

Document Format Files

Seq Description Document Type Size
1 DEF 14A titanpharma_def14a.htm   iXBRL DEF 14A 588734
6 GRAPHIC img_001.jpg GRAPHIC 47850
7 GRAPHIC img_002.jpg GRAPHIC 52821
  Complete submission text file 0001829126-23-003606.txt   1294383

Data Files

Seq Description Document Type Size
2 XBRL DEFINITION FILE ttnp-20221231_def.xml EX-101.DEF 10269
3 XBRL LABEL FILE ttnp-20221231_lab.xml EX-101.LAB 56153
4 XBRL PRESENTATION FILE ttnp-20221231_pre.xml EX-101.PRE 43102
5 XBRL SCHEMA FILE ttnp-20221231.xsd EX-101.SCH 5081
10 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_def14a_htm.xml XML 54169
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-13341 | Film No.: 23938066
SIC: 2836 Biological Products, (No Diagnostic Substances)